ZVI FUKS, MD
Radiology at York Ave, New York, NY
License number
New York 157760
Category
Radiology
Type
Therapeutic Radiology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(212) 639-2000
Organization information
See more information about ZVI FUKS at bizstanding.comMemorial Sloan Kettering - Zvi Fuks MD
1275 York Ave #SM1, New York, NY 10065
Categories:
Oncology Physicians & Surgeons, Radiology Physicians & Surgeons
Phone:
(212) 639-2000 (Phone)
Professional information
Zvi Fuks, New York NY
Specialties:
Radiologist
Address:
1275 York Ave, New York, NY 10065
633 3Rd Ave, New York, NY 10017
633 3Rd Ave, New York, NY 10017
Education:
Hadassah Medical School - Doctor of Medicine
Board certifications:
American Board of Radiology Certification in Therapeutic Radiology (Radiology)
Dr. Zvi Fuks, New York NY - MD (Doctor of Medicine)
Specialties:
Radiology, Therapeutic Radiology
Address:
MEMORIAL RADIATION ONCOLOGY GROUP
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
Certifications:
Therapeutic Radiology
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
MEMORIAL RADIATION ONCOLOGY GROUP
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
Hadassah Medical School, The Hebrew University Of Jerusalem
Graduated: 1960
Hadassah Medical School, The Hebrew University Of Jerusalem
Graduated: 1960
Heparanase Derived From Human Sk-Hep-1 Cell Line
US Patent:
5362641, Nov 8, 1994
Filed:
Jan 8, 1992
Appl. No.:
7/768900
Inventors:
Zvi Fuks - New York NY
Israel Vlodavsky - Gilo, IL
Israel Vlodavsky - Gilo, IL
Assignee:
Hadassah Medical Organization Kiryat Hadassah - Jerusalem
International Classification:
C12N 926, C12N 924, C12N 942, C12N 914
US Classification:
435209
Abstract:
The present invention relates to a substantially purified heparanase obtained from the human SK-HEP-1 cell line and a method to purify the heparanase from a centrifuged dialyzed homogenate of the SK-HEP-1 cells or a cell culture medium containing the heparanase from the SK-HEP-1 cell line.
Method And Composition To Increase Radiation-Induced Tumor Therapeutic Effects
US Patent:
2012025, Oct 4, 2012
Filed:
Dec 7, 2010
Appl. No.:
13/513890
Inventors:
Richard N. Kolesnick - New York NY, US
Branka Stancevic - New York NY, US
Michel Sadelain - New York NY, US
Zvi Fuks - New York NY, US
Nira Varda-Bloom - Hod-Hasharon, IL
Dror Harats - Ramat-Gan, IL
Branka Stancevic - New York NY, US
Michel Sadelain - New York NY, US
Zvi Fuks - New York NY, US
Nira Varda-Bloom - Hod-Hasharon, IL
Dror Harats - Ramat-Gan, IL
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER ("MSKCC") - New York NY
International Classification:
C12N 15/55, A61K 31/7088, A61P 35/00, C12N 15/63
US Classification:
514 44 R, 536 232, 4353201
Abstract:
Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
Method Of Killing Sarcoma Cells Using Fludarabine Phosphate And Ionizing Radiation
US Patent:
5081110, Jan 14, 1992
Filed:
Dec 13, 1988
Appl. No.:
7/283734
Inventors:
Jae H. Kim - Tenafly NJ
Alan A. Alfieri - Garden City NY
Sang H. Kim - Flushing NY
Zvi Fuks - New York NY
Alan A. Alfieri - Garden City NY
Sang H. Kim - Flushing NY
Zvi Fuks - New York NY
Assignee:
Sloan-Kettering Institute For Cancer Research - New York NY
International Classification:
A61K 3170, A61W 500
US Classification:
514 47
Abstract:
This invention provides a method of killing sarcoma cells in a patient by administering to the patient an effective amount of fludarabine phosphate effective to inhibit the repair of potentially lethal damage to the sarcoma cells and exposing the patient to an effective amount of ionizing radiation, effective to kill the sarcoma tumor cells in the patient.